Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose.
Am Heart J
; 245: 19-28, 2022 03.
Article
en En
| MEDLINE
| ID: mdl-34736855
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Aspirina
/
Fibrinolíticos
Tipo de estudio:
Clinical_trials
/
Etiology_studies
/
Observational_studies
Límite:
Humans
Idioma:
En
Revista:
Am Heart J
Año:
2022
Tipo del documento:
Article
Pais de publicación:
Estados Unidos